Pancreatic cancer is one of the deadliest terminal illnesses there is and it affects 3% of all Americans.

It mainly attacks the pancreas and often stops it from functioning all together. Treatment for such is possible, but rarely does it give the results. The people victimized by the disease now have the possibility to be able to live just that little bit longer for those they love even with their disease: as of recently, scientists have made a great discovery that may change how we help people who have this affliction.

Recently there has been a breakthrough in research for how we treat pancreatic cancer and it comes in the form of the experimental drug known as daraxonrasib. This drug is able to exponentially extend the lifespan of patients with this type of cancer and it works by targeting a protein in cells called KRAS which is the main problem with treating pancreatic cancer as it by many experts has been described as a “greasy ball impervious to assault.”

This way of the protein’s complexion has led to it becoming very hard to make any actually effective medication for this, but with this new drug, the molecules are directly bound together to shut down the protein thus being able to leave the body open for the drug to treat the pancreatic cancer. 

This new treatment is so revolutionary, that it has opened the doors to further cancer type treatment for so many others and will therefore be able to greatly improve the quality of medicine and cancer research productivity.